The Dangers of Hype: How a Bold Claim and Sensational Media Unraveled a Company

The Dangers of Hype: How a Bold Claim and Sensational Media Unraveled a Company

Magnetic resonance imaging of the brain.

(© Maxim Pavlov/Fotolia)


Keep Reading Keep Reading
Addison Nugent
Addison Nugent is a professional freelance journalist based out of Paris, France. Like so many Americans before her, she fell in love with the French capital at a young age and never left. She graduated from the Sorbonne's Master of the Arts literary research program with honors in 2016, and has since pursued a career in journalism. She has accumulated a diverse portfolio of published work that includes investigative pieces, in-depth profiles, historical deep dives, and tech news. Her work has been featured in such publications as OZY, Vice Motherboard, Atlas Obscura, Dazed Digital and Messy Nessy Chic.
How sharing, hearing, and remembering positive stories can help shape our brains for the better

Across cultures and through millennia, human beings have always told stories. Whether it’s a group of boy scouts around a campfire sharing ghost stories or the paleolithic Cro-Magnons etching pictures of bison on cave walls, researchers believe that storytelling has been universal to human beings since the development of language.

But storytelling was more than just a way for our ancestors to pass the time. Researchers believe that storytelling served an important evolutionary purpose, helping humans learn empathy, share important information (such as where predators were or what berries were safe to eat), as well as strengthen social bonds. Quite literally, storytelling has made it possible for the human race to survive.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.